

Workshop: 21st Century Trials in New-Onset T1D



Critical Path Institute's Type 1 Diabetes consortium held a virtual workshop, 21st Century Trials in New-Onset T1D: How the use of C-Peptide can accelerate the development of next-gen disease-modifying therapies for T1D.

The purpose of this scientific workshop was to gather researchers, physicians, industry, patient advocacy and regulators in order to discuss the current evidence for the use of c-peptide as an endpoint in clinical trials of new-onset T1D. We aim to reach conclusion and clarity on next steps.?

The agenda included:

- Session 0: Welcome and Introductory Remarks
- Session I: C-peptide, T1D and unmet need
- Session II: Current state of clinical trials in New-Onset T1D
- Session III: C-peptide and clinical benefits in T1D
- Session IV: How can C-peptide be used to accelerate drug development in New-Onset T1D?
- Panel Discussion: Big picture: where do we stand and what's next?

[Watch the recordings](#)

[View the briefing Doc](#)